Search Results
Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI)-Aristotle University of Thessaloniki (AUTH), Balkan Center, Thessaloniki, Greece
Search for other papers by Vasileios F Pegios in
Google Scholar
PubMed
Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI)-Aristotle University of Thessaloniki (AUTH), Balkan Center, Thessaloniki, Greece
Search for other papers by Eustathios Kenanidis in
Google Scholar
PubMed
Department of Trauma and Orthopaedics, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Search for other papers by Stavros Tsotsolis in
Google Scholar
PubMed
Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI)-Aristotle University of Thessaloniki (AUTH), Balkan Center, Thessaloniki, Greece
Search for other papers by Michael Potoupnis in
Google Scholar
PubMed
Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI)-Aristotle University of Thessaloniki (AUTH), Balkan Center, Thessaloniki, Greece
Search for other papers by Eleftherios Tsiridis in
Google Scholar
PubMed
Purpose
-
The main indication of bisphosphonates (BPs) is osteoporosis treatment. However, there is growing interest in the peri- and postoperative use of BPs to mitigate total hip arthroplasty (THA) aseptic loosening (AL) risk. This systematic review aimed to evaluate the implant survival and the AL rate in patients with elective THA receiving BPs compared to those that do not receive BPs. Secondary outcomes included the comparison of revision rate, postoperative complications, and patients’ functional scores.
Methods
-
This systematic review was conducted under the PRISMA 2020 guidelines with a pre-registered PROSPERO protocol. Three engines and grey literature were searched up until May 2022. Randomized and nonrandomized controlled trials and comparative cohort studies assessing BP and control therapy impact on THA survival were included.
Results
-
Twelve studies embraced the inclusion criteria. A total of 99 678 patients and 99 696 THAs were included; 10 025 patients received BPs (BP group), and 89 129 made up the control group. The overall revision and AL rates were lower in the BP group (2.17% and 1.85%) than in the control group (4.06% and 3.2%). Periprosthetic fracture (PPF) cases were higher in the BP group (0.24%) than in the control group (0.04%); however, the majority of PPF cases were derived from a single study. Further complication risk was similar between groups. Most studies reported comparable functional scores between groups.
Conclusion
-
BP treatment after elective THA seems to reduce the overall revision and AL risk. Other complications’ risk and functional scores were similar between groups. Further high-quality studies are needed to validate the results due to the multifactorial AL pathogenesis.
Center of Orthopaedics and Regenerative Medicine (C.O.RE.) – Center of Interdisciplinary Research and Innovation (C.I.R.I.) – Aristotle University Thessaloniki, Balkan Center, Hellas, Greece
Hôpital de la Tour, Geneva, Switzerland
Search for other papers by Eustathios Kenanidis in
Google Scholar
PubMed
Search for other papers by Konstantinos Kapriniotis in
Google Scholar
PubMed
Search for other papers by Panagiotis Anagnostis in
Google Scholar
PubMed
Center of Orthopaedics and Regenerative Medicine (C.O.RE.) – Center of Interdisciplinary Research and Innovation (C.I.R.I.) – Aristotle University Thessaloniki, Balkan Center, Hellas, Greece
Search for other papers by Michael Potoupnis in
Google Scholar
PubMed
Search for other papers by Panayiotis Christofilopoulos in
Google Scholar
PubMed
Center of Orthopaedics and Regenerative Medicine (C.O.RE.) – Center of Interdisciplinary Research and Innovation (C.I.R.I.) – Aristotle University Thessaloniki, Balkan Center, Hellas, Greece
Search for other papers by Eleftherios Tsiridis in
Google Scholar
PubMed
-
Total hip arthroplasty (THA) in sickle cell disease (SCD) patients can be a challenging procedure.
-
This systematic review evaluated the revision rate, functional outcomes and complications of THA in sicklers.
-
A systematic search was conducted according to the PRISMA guidelines, using four search engines from inception to May 2019.
-
Fifteen studies with 971 THAs were included. There were 437 cemented and 520 uncemented THAs.
-
There were 164 revision THAs (16.8%); 52 uncemented and 105 cemented THAs.
-
Forty-two infections were recorded; 16 infections for cemented and 23 for uncemented THAs.
-
Fifty-seven cups, 26 stems, eight cup/stem with aseptic loosening that were more frequently cemented were reported. The 28 unspecified aseptic loosening cases were more frequently uncemented THAs.
-
All studies demonstrated the functional improvement of patients.
-
There were 109 medical complications (14.3%). Sickle cell crises (SCC) and transfusion reactions were most usually recorded.
-
Forty-six intraoperative complications (4.7%) were reported; 18 femoral fractures, four acetabular and 18 femoral perforations. Seventeen femoral fractures occurred during uncemented THA.
-
THA in SCD is still related to a high risk of complications. The outcomes in properly selected sicklers have been improved. Perioperative adequate hydration, warming, oxygen supply and transfusion protocols are mandated to prevent SCC and transfusion reactions. The surgeon must be prepared to deal with a high rate of intraoperative fractures and have different implant options readily available. No definite conclusion can be made regarding the best fixation mode. Cemented implants demonstrated a higher revision rate and uncemented implants a higher risk for intraoperative complications.
Cite this article: EFORT Open Rev 2020;5:180-188. DOI: 10.1302/2058-5241.5.190038
Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI)-Aristotle University of Thessaloniki (AUTH), Balkan Center, Buildings A & B, Thessaloniki, Greece
Trauma and Orthopaedics Department, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Search for other papers by Stavros Tsotsolis in
Google Scholar
PubMed
Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI)-Aristotle University of Thessaloniki (AUTH), Balkan Center, Buildings A & B, Thessaloniki, Greece
Search for other papers by Eustathios Kenanidis in
Google Scholar
PubMed
Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI)-Aristotle University of Thessaloniki (AUTH), Balkan Center, Buildings A & B, Thessaloniki, Greece
Search for other papers by Vasileios F Pegios in
Google Scholar
PubMed
Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI)-Aristotle University of Thessaloniki (AUTH), Balkan Center, Buildings A & B, Thessaloniki, Greece
Search for other papers by Michael Potoupnis in
Google Scholar
PubMed
Centre of Orthopaedic and Regenerative Medicine (CORE), Center for Interdisciplinary Research and Innovation (CIRI)-Aristotle University of Thessaloniki (AUTH), Balkan Center, Buildings A & B, Thessaloniki, Greece
Search for other papers by Eleftherios Tsiridis in
Google Scholar
PubMed
Background
-
This comprehensive systematic review aims to assess the literature regarding the risk of postoperative complications in patients undergoing total joint arthroplasty (TJA) with concomitant thyroid dysfunction.
Methods
-
Studies were identified by searching PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, and ClinicalTrials.gov (end of search: May 2022).
Inclusion criteria
-
Randomized control and case-control studies, cohort and observational clinical studies were included, which focused on postoperative complications and outcomes of patients undergoing TJA operations of major joints (knee, hip, ankle, elbow). All studies were assessed according to their level of evidence, the number and age of patients, and treatment complications.
Analysis
-
Nine studies were included in this review that demonstrated a higher risk of postoperative anemia, perioperative blood loss, hemoglobin decrease, and transfusion rates in hypothyroid patients after TJA.
Results
-
Hypothyroidism has been identified as a potential but modifiable risk factor for increased rates of deep venous thrombosis, acute kidney injury, pneumonia, and non-specified cardiac complications among hypothyroid patients who underwent TJA as well as increased rates of periprosthetic joint infection. No significant differences in the prosthesis-related mechanical complication rates have been calculated when comparing hypothyroid and euthyroid patients.
